Generic Name and Formulations:
Bromocriptine mesylate (micronized) 0.8mg; tabs.
Indications for CYCLOSET:
Adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.
Limitations Of use:
Not for treating type 1 diabetes or ketoacidosis. Limited efficacy data in combination with thiazolidinediones. Efficacy has not been confirmed in combination with insulin.
Take with food in the AM, within 2hrs of waking. Initially 0.8mg once daily; may increase by 0.8mg per week as tolerated until max 4.8mg/day. Usual range: 1.6–4.8mg/day. Concomitant moderate CYP3A4 inhibitors (eg, erythromycin): max 1.6mg once daily. Concomitant strong CYP3A4 inhibitors (eg, azole antimycotics, protease inhibitors): avoid.
Syncopal migraines. Nursing mothers. Allergy to ergot-related drugs.
Monitor orthostatic vital signs initially and periodically during therapy. Severe psychotic disorders: not recommended. Renal or hepatic impairment. Pregnancy (Cat.B).
Dopamine agonist (ergot deriv).
See Adult. Concomitant selective 5-HT1B agonists (eg, sumatriptan), sympathomimetic drugs >10 days, ergot-related drugs within 6hrs, other dopamine agonists and antagonists, including neuroleptics (eg, clozapine, olanzapine, ziprasidone) and metoclopramide: not recommended. Potentiated by CYP3A4 inhibitors and antagonized by CYP3A4 inducers (eg, rifampin, dexamethasone). Potentiates antihypertensives; caution. May potentiate highly protein bound drugs (eg, salicylates, sulfonamides, chloramphenicol, probenecid).
Nausea, vomiting, fatigue, dizziness, headache; hypotension, syncope, somnolence, hypoglycemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC